Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy

BACKGROUND: Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autoph...

全面介紹

Na minha lista:
書目詳細資料
發表在:Respir Res
Main Authors: Kurita, Yusuke, Araya, Jun, Minagawa, Shunsuke, Hara, Hiromichi, Ichikawa, Akihiro, Saito, Nayuta, Kadota, Tsukasa, Tsubouchi, Kazuya, Sato, Nahoko, Yoshida, Masahiro, Kobayashi, Kenji, Ito, Saburo, Fujita, Yu, Utsumi, Hirofumi, Yanagisawa, Haruhiko, Hashimoto, Mitsuo, Wakui, Hiroshi, Yoshii, Yutaka, Ishikawa, Takeo, Numata, Takanori, Kaneko, Yumi, Asano, Hisatoshi, Yamashita, Makoto, Odaka, Makoto, Morikawa, Toshiaki, Nakayama, Katsutoshi, Kuwano, Kazuyoshi
格式: Artigo
語言:Inglês
出版: BioMed Central 2017
主題:
Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457546/
https://ncbi.nlm.nih.gov/pubmed/28577568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-017-0600-3
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍